Nykode Enters New Phase With Regeneron Vaccine Pact
US Major Pays $30m Upfront And Takes Stake
Regeneron is investing heavily to advance five vaccine programs with Nykode Therapeutics, the Norwegian company formerly known as Vaccibody.
You may also be interested in...
The London-based biotech is hoping to turn the dream of liver organ transplant without the need for lifelong immunosuppression into reality.
The value-based procurement scheme in China is about to be implemented on insulin products and while most of Novo Nordisk's therapies were included in the tender, price cuts are going to impact global sales growth by 3% next year.
Despite recent setbacks for Roche and Wave's respective antisense offerings, both those two firms and a number of other companies are trying a variety of approaches to find a treatment for Huntington's.